New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view

Kidney International

Volumn 79, Issue 1, 2011, Pages 33-45

  Lopez Novoa, Jose M ^a,b   Quiros, Yaremi ^a,b   Vicente, Laura ^a,b   Morales, Ana I ^a,b   Lopez Hernandez, Francisco J ^a,b,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Instituto Reina Sofía de Investigación Nefrológica Fundación Iñigo Álvarez de Toledo   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

aminoglycoside antibiotics; gentamicin; nephrotoxicity; pathophysiology; prevention

Indexed keywords

ANTIOXIDANT; ENDOTHELIN 1; GENTAMICIN; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2;

AMINOACIDURIA; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG EFFECT; DRUG INDUCED DISEASE; ENDOPLASMIC RETICULUM STRESS; ENZYMURIA; FOLLOW UP; GLOMERULUS; GLOMERULUS FILTRATION RATE; GLUCOSURIA; KIDNEY BLOOD FLOW; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 78650292754     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.337     Document Type: Review

References (167)

1. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 2009; 23: 1053-1075.
2. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99.
3. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999; 74: 519-528.
4. Laurent G, Carlier MB, Rollman B et al. Mechanism aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol 1982; 31: 3861-3870.
5. Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990; 40: 2383-2392.
6. Kacew S, Bergeron MG. Pathogenic factors in aminoglycoside induced nephrotoxicity. Toxicol Lett 1990; 51: 241-259. (Pubitemid 20141914)
7. De Broe ME, Paulus GJ, Verpooten GA et al. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int 1984; 25: 643-652.
8. Leehey DJ, Braun BI, Tholl DA et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol 1993; 4: 81-90.
9. Bertino Jr JS, Booker LA, Franck PA et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173-179.
10. Kays SE, Crowell WA, Johnson MA. Iron supplementation increases gentamicin nephrotoxicity in rats. J Nutr 1992; 121: 1869-1872.
11. Madsen KM, Park CH. Lysosome distribution and cathepsin B and L activity along the rabbit proximal tubule. Am J Physiol 1987; 253: 290-301.
12. Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother 1981; 19: 859-866.
13. Plaut ME, Schentag JJ, Jusko WJ. Nephrotoxicity with gentamicin or tobramycin. Lancet 1979; 2: 526-527.
14. Moore RD, Smith CR, Lipsky JJ et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352-357.
15. Prins JM, Weverling GJ, de Blok K et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996; 40: 2494-2499.
16. Verpooten GA, Giuliano RA, Verbist L et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22-27.
17. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27(Suppl C): 41-47.
18. Trollfors B, Alestig K, Krantz I et al. Quantitative nephrotoxicity of gentamicin in nontoxic doses. J Infect Dis 1980; 141: 306-309.
19. Klastersky J, Hensgens C, Henri A et al. Comparative clinical study of tobramycin and gentamicin. Antimicrob Agents Chemother 1974; 5: 133-138.
20. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43: 1003-1012.
21. Parsons PP, Garland HO, Harpur ES et al. Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury. Br J Pharmacol 1997; 122: 570-576.
22. Banday AA, Farooq N, Priyamvada S et al. Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. Life Sci 2008; 82: 450-459.
23. Li J, Li QX, Xie XF et al. Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in rats. Eur J Pharmacol 2009; 620: 97-104.
24. Laurent G, Maldague P, Carlier MB et al. Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats. Antimicrob Agents Chemother 1983; 24: 586-593.
25. El Mouedden M, Laurent G, Mingeot-Leclercq MP et al. Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob Agents Chemother 2000; 44: 665-675.
26. Edwards JR, Diamantakos EA, Peuler JD et al. A novel method for the evaluation of proximal tubule epithelial cellular necrosis in the intact rat kidney using ethidium homodimer. BMC Physiol 2007; 7: 1.
27. El Mouedden M, Laurent G, Mingeot-Leclercq MP et al. Gentamicin-induced apoptosis in renal cell lines and embryonic rat fibroblasts. Toxicol Sci 2000; 56: 229-239.
28. Pessoa EA, Convento MB, Silva RG et al. Gentamicin-induced preconditioning of proximal tubular LLC-PK1 cells stimulates nitric oxide production but not the synthesis of heat shock protein. Braz J Med Biol Res 2009; 42: 614-620.
29. Shibuya H, Kato Y, Saito M et al. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res 2003; 13: 457-464.
30. Saito Y, Nishio K, Ogawa Y et al. Turning point in apoptosis/necrosis induced by hydrogen peroxide. Free Radic Res 2006; 40: 619-630.
31. Chiarugi A. 'Simple but not simpler': toward a unified picture of energy requirements in cell death. FASEB J 2005; 19: 1783-1788.
32. Steinbach JP, Wolburg H, Klumpp A et al. Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death. J Neurochem 2005; 92: 1340-1349.
33. Khan S, Cleveland RP, Koch CJ et al. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999; 79: 1089-1099.
34. Módis K, Gero D, Nagy N et al. Cytoprotective effects of adenosine and inosine in an in vitro model of acute tubular necrosis. Br J Pharmacol 2009; 158: 1565-1578.
35. Servais H, Jossin Y, Van Bambeke F et al. Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob Agents Chemother 2006; 50: 1213-1221.
36. Wu Y, Connors D, Barber L et al. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. Toxicol In Vitro 2009; 23: 1170-1178.
37. Pattyn VM, Verpooten GA, Giuliano RA et al. Effect of hyperfiltration, proteinuria and diabetes mellitus on the uptake kinetics of gentamicin in the kidney cortex of rats. J Pharmacol Exp Ther 1988; 244: 694-698.
38. Fujiwara K, Shin M, Matsunaga H et al. Light-microscopic immunocytochemistry for gentamicin and its use for studying uptake of the drug in kidney. Antimicrob Agents Chemother 2009; 53: 3302-3307.
39. Schmitz C, Hilpert J, Jacobsen C et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277: 618-622.
40. Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979; 15: 335-345.
41. Silverblatt F. Pathogenesis of nephrotoxicity of cephalosporins and aminoglycosides: a review of current concepts. Rev Infect Dis 1982; 4(Suppl): S360-S365.
42. Giuliano RA, Paulus GJ, Verpooten GA et al. Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int 1984; 26: 838-847.
43. Nonclercq D, Wrona S, Toubeau G et al. Tubular injury and regeneration in the rat kidney following acute exposure to gentamicin: a time-course study. Ren Fail 1992; 14: 507-521.
44. Mingeot-Leclercq MP, Brasseur R, Schanck A. Molecular parameters involved in aminoglycoside nephrotoxicity. J Toxicol Environ Health 1995; 44: 263-300.
45. Ramsammy LS, Josepovitz C, Lane B et al. Effect of gentamicin on phospholipid metabolism in cultured rabbit proximal tubular cells. Am J Physiol 1989; 256: C204-C213.
46. Abdel-Gayoum AA, Ali BH, Ghawarsha K et al. Plasma lipid profile in rats with gentamicin-induced nephrotoxicity. Hum Exp Toxicol 1993; 12: 371-375.
47. Tulkens PM. Nephrotoxicity of aminoglycoside antibiotics. Toxicol Lett 1989; 46: 107-123.
48. Kaloyanides GJ. Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity. Ren Fail 1992; 14: 351-357.
49. Ramsammy LS, Josepovitz C, Lane BP et al. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat. J Pharmacol Exp Ther 1989; 250: 149-153.
50. Beauchamp D, Laurent G, Maldague P et al. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther 1990; 255: 858-866.
51. Swan SK, Kohlhepp SJ, Kohnen PW et al. Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity. Antimicrob Agents Chemother 1991; 35: 2591-2595.
52. Ramsammy L, Josepovitz C, Lane B et al. Polyaspartic acid inhibits gentamicin-induced perturbations of phospholipid metabolism. Am J Physiol 1990; 258: C1141-C1149.
53. Lipsky JJ, Cheng L, Sacktor B et al. Gentamicin uptake by renal tubule brush border membrane vesicles. J Pharmacol Exp Ther 1980; 215: 390-393.
54. Frommer JP, Senekjian HO, Babino H et al. Intratubular microinjection study of gentamicin transport in the rat. Miner Electrolyte Metab 1983; 9: 108-112.
55. Ngaha EO, Ogunleye IO. Studies on gentamicin-induced labilization of rat kidney lysosomes in vitro. Possible protection by selenium. Biochem Pharmacol 1983; 32: 2659-2664.
56. Regec AL, Trump BF, Trifillis AL. Effect of gentamicin on the lysosomal system of cultured human proximal tubular cells. Endocytotic activity, lysosomal pH and membrane fragility. Biochem Pharmacol 1989; 38: 2527-2534.
57. Mather M, Rottenberg H. Polycations induce the release of soluble intermembrane mitochondrial proteins. Biochim Biophys Acta 2001; 1503: 357-368.
58. Morales AI, Detaille D, Prieto M et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 2010; 77: 861-869.
59. Simmons Jr CF, Bogusky RT, Humes HD. Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation. J Pharmacol Exp Ther 1980; 214: 709-715.
60. Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 1988; 81: 334-341.
61. Cuzzocrea S, Mazzon E, Dugo L et al. A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2002; 450: 67-76.
62. Horibe T, Matsui H, Tanaka M et al. Gentamicin binds to the lectin site of calreticulin and inhibits its chaperone activity. Biochem Biophys Res Commun 2004; 323: 281-287.
63. Schnellmann RG, Williams SW. Proteases in renal cell death: calpains mediate cell death produced by diverse toxicants. Ren Fail 1998; 20: 679-686.
64. Chwieralski CE, Welte T, Bühling F. Cathepsin-regulated apoptosis. Apoptosis 2006; 11: 143-149.
65. Yin XM. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 2006; 369: 7-19.
66. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007; 32: 37-43.
67. Bennett WM, Mela-Riker LM, Houghton DC et al. Microsomal protein synthesis inhibition: an early manifestation of gentamicin nephrotoxicity. Am J Physiol 1988; 255: F265-F269.
68. Monteil C, Leclere C, Fillastre JP et al. Characterization of gentamicin-induced dysfunctions in vitro: the use of optimized primary cultures of rabbit proximal tubule cells. Ren Fail 1993; 15: 475-483.
69. Buchanan JH, Stevens A, Sidhu J. Aminoglycoside antibiotic treatment of human fibroblasts: intracellular accumulation, molecular changes and the loss of ribosomal accuracy. Eur J Cell Biol 1987; 43: 141-147.
70. Shimizu A, Takumida M, Anniko M et al. Calpain and caspase inhibitors protect vestibular sensory cells from gentamicin ototoxicity. Acta Otolaryngol 2003; 123: 459-465.
71. Peyrou M, Hanna PE, Cribb AE. Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 2007; 99: 346-353. (Pubitemid 47250391)
72. Peyrou M, Cribb AE. Effect of endoplasmic reticulum stress preconditioning on cytotoxicity of clinically relevant nephrotoxins in renal cell lines. Toxicol In Vitro 2007; 21: 878-886.
73. Sorribas V, Halaihel N, Puttaparthi K et al. Gentamicin causes endocytosis of Na/Pi cotransporter protein (NaPi-2). Kidney Int 2001; 59: 1024-1036.
74. Levi M, Cronin RE. Early selective effects of gentamicin on renal brush-border membrane Na-Pi cotransport and Na-H exchange. Am J Physiol 1990; 258: F1379-F1387.
75. Skopicki HA, Zikos D, Sukowski EJ et al. Gentamicin inhibits carrier-mediated dipeptide transport in kidney. Am J Physiol 1996; 270: F531-F538.
76. Todd JH, Sens DA, Hazen-Martin DJ et al. Aminoglycoside antibiotics alter the electrogenic transport properties of cultured human proximal tubule cells. Toxicol Pathol 1992; 20: 608-616.
77. Fukuda Y, Malmborg AS, Aperia A. Gentamicin inhibition of Na+,K(+)-ATPase in rat kidney cells. Acta Physiol Scand 1991; 141: 27-34.
78. Sassen MC, Kim SW, Kwon TH et al. Dysregulation of renal sodium transporters in gentamicin-treated rats. Kidney Int 2006; 70: 1026-1037.
79. DiBona DR, Powell Jr WJ. Quantitative correlation between cell swelling and necrosis in myocardial ischemia in dogs. Circ Res 1980; 47: 653-665.
80. Lieberthal W, Levine JS. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol 1996; 271: F477-F488. (Pubitemid 26328278)
81. Foster JE, Harpur ES, Garland HO. An investigation of the acute effect of gentamicin on the renal handling of electrolytes in the rat. J Pharmacol Exp Ther 1992; 261: 38-43.
82. Moestrup SK, Cui S, Vorum H et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96: 1404-1413.
83. Cui S, Verroust PJ, Moestrup SK et al. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996; 271: F900-F907.
84. Nagai J, Katsube T, Murakami T et al. Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney. J Pharm Pharmacol 2002; 54: 1491-1496.
85. Nagai J, Saito M, Adachi Y et al. Inhibition of gentamicin binding to rat renal brush-border membrane by megalin ligands and basic peptides. J Control Release 2006; 112: 43-50.
86. Neugarten J, Aynedjian HS, Bank N. Role of tubular obstruction in acute renal failure due to gentamicin. Kidney Int 1983; 24: 330-335.
87. Rivas-Cabañ ero L, García-Bastos JL, Arevalo M et al., Effect of gentamicin treatment on glutamine and lactate metabolism by the renal cortex of the rat. Arch Int Physiol Biochim Biophys., 1993, 101, 193-196.
88. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 2003; 18: 169-174.
89. Blantz RC, Deng A, Miracle CM et al. Regulation of kidney function and metabolism: a question of supply and demand. Trans Am Clin Climatol Assoc 2007; 118: 23-43.
90. Komlosi P, Bell PD, Zhang ZR. Tubuloglomerular feedback mechanisms in nephron segments beyond the macula densa. Curr Opin Nephrol Hypertens 2009; 18: 57-62.
91. Thomson SC, Vallon V, Blantz RC. Resetting protects efficiency of tubuloglomerular feedback. Kidney Int Suppl 1998; 67: S65-S70.
92. Deng A, Wead LM, Blantz RC. Temporal adaptation of tubuloglomerular feedback: effects of COX-2. Kidney Int 2004; 66: 2348-2353.
93. Mart́?nez-Salgado C, López-Hernández FJ, López-Novoa JM Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007, 223, 86-98.
94. Schor N, Ichikawa I, Rennke HG et al. Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int 1981; 19: 288-296.
95. Dos Santos OF, Boim MA, Barros EJ et al. Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity. Kidney Int 1991; 40: 742-747.
96. Mart́?nez-Salgado C, Rodr?́guez-Barbero A, Eleno N et al., Gentamicin induces Jun-AP1 expression and JNK activation in renal glomeruli and cultured mesangial cells. Life Sci., 2005, 77, 2285-2298.
97. Stojiljkovic N, Mihailovic D, Veljkovic S et al. Glomerular basement membrane alterations induced by gentamicin administration in rats. Exp Toxicol Pathol 2008; 60: 69-75.
98. De-Barros-e-Silva ML, Varanda WA, Lachat JJ et al. Glomerular permeability to macromolecules in gentamicin-treated rats. Braz J Med Biol Res 1992; 25: 409-417.
99. Luft FC, Aronoff GR, Evan AP et al. The effect of aminoglycosides on glomerular endothelium: a comparative study. Res Commun Chem Pathol Pharmacol 1981; 34: 89-95.
100. Cojocel C, Docius N, Maita K et al. Renal ultrastructural and biochemical injuries induced by aminoglycosides. Environ Health Perspect 1984; 57: 293-299.
101. Maita K, Cojocel C, Dociu N et al. Effects of aminoglycosides on glomerular ultrastructure. Pharmacology 1984; 29: 292-300.
102. Rodriguez-Barbero A, Rodriguez-Lopez AM, Gonzalez-Sarmiento R et al. Gentamicin activates rat mesangial cells. A role for platelet activating factor. Kidney Int 1995; 47: 1346-1353.
103. Mart?́nez-Salgado C, Rodŕ?guez-Barbero A, Rodŕ?guez-Puyol D et al., Involvement of phospholipase A2 in gentamicin-induced rat mesangial cell activation. Am J Physiol 1997, 273, F60-F66.
104. Valdivielso JM, Rivas-Cabañero L, Morales AI et al. Increased renal glomerular endothelin-1 release in gentamicin-induced nephrotoxicity. Int J Exp Pathol 1999; 80: 265-270.
105. Duque I, García-Escribano C, Rodr?́guez-Puyol M et al. Effects of reactive oxygen species on cultured rat mesangial cells and isolated rat glomeruli. Am J Physiol 1992; 263: F466-F473.
106. Friedlander G, Pirotzky E, Amiel C et al. Renal effects of platelet-activating factor in the rat. Agents Actions 1987; 22: 165-170.
107. Santos CX, Tanaka LY, Wosniak J et al. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009; 11: 2409-2427.
108. Ló pez-Novoa JM, Potential role of platelet activating factor in acute renal failure. Kidney Int 1999 55, 1672-1682.
109. Rodriguez-Barbero A, Bosque E, Rivas-Cabañ ero L et al. Effect of platelet activating factor antagonist treatment on gentamicin nephrotoxicity. Mediators Inflamm 1992; 1: 23-26.
110. Rodriguez-Barbero A, López-Novoa JM, Arévalo M. Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Exp Nephrol 1997; 5: 47-54.
111. Martínez-Salgado C, Eleno N, Morales AI et al., Gentamicin treatment induces simultaneous mesangial proliferation and apoptosis in rats. Kidney Int., 2004 65 2161-2171.
112. Rivas-Cabañero L, Montero A, López-Novoa JM. Increased glomerular nitric oxide synthesis in gentamicin-induced renal failure. Eur J Pharmacol 1994; 270: 119-121.
113. Rivas-Cabañero L, Rodŕ?guez-López AM, Mart́?nez-Salgado C et al. Gentamicin treatment increases mesangial cell nitric oxide production. Exp Nephrol 1997; 5: 23-30.
114. Leung JC, Marphis T, Craver RD et al. Altered NMDA receptor expression in renal toxicity: protection with a receptor antagonist. Kidney Int 2004; 66: 167-176.
115. Pedraza-Chaverŕ? J, Barrera D, Maldonado PD et al., S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin Pharmacol, 2004, 30 4-5.
116. Hishida A, Nakajima T, Yamada M et al. Roles of hemodynamic and tubular factors in gentamicin-mediated nephropathy. Ren Fail 1994; 16: 109-116.
117. Morales AI, Buitrago JM, Santiago JM et al. Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid Redox Signal 2002; 4: 893-898.
118. Klotman PE, Yarger WE. Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin. Kidney Int 1983; 24: 638-643.
119. Persson PB. Physiological regulation of renal blood flow and glomerular filtration rate by the endothelium and smooth muscle. Blood Purif 1997; 15: 219-227.
120. Papanikolaou N, Peros G, Morphake P et al. Does gentamicin induce acute renal failure by increasing renal TXA2 synthesis in rats? Prostaglandins Leukot Essent Fatty Acids 1992; 45: 131-136.
121. Assael BM, Chiabrando C, Gagliardi L et al. Prostaglandins and aminoglycoside nephrotoxicity. Toxicol Appl Pharmacol 1985; 78: 386-394.
122. Fö rstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459: 923-939.
123. Yorulmaz O et al. Protective effect of L-arginine intake on the impaired renal vascular responses in the gentamicin-treated rats. Nephron Physiol 2005; 100: 13-20.
124. Gergawy M, Vollrath B, Cook D. The mechanism by which aminoglycoside antibiotics cause vasodilation of canine cerebral arteries. Br J Pharmacol 1998; 125: 1150-1157.
125. Wickman G, Nessim MA, Cook DA et al. The polycationic aminoglycosides modulate the vasoconstrictive effects of endothelin: relevance to cerebral vasospasm. Br J Pharmacol 2001; 133: 5-12.
126. De Nucci G, Gryglewski RJ, Warner TD et al. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85: 2334-2338. (Pubitemid 24315886)
127. Hines J, Vinores SA, Campochiaro PA. Evolution of morphologic changes after intravitreous injection of gentamicin. Curr Eye Res 1993; 12: 521-529.
128. Moran K, Mulhall J, Kelly D et al. Morphological changes and alterations in regional intrarenal blood flow induced by graded renal ischemia. J Urol 1992; 148: 463-466.
129. Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol 1995; 26: 1477-1487.
130. Marumo F et al. Increased renal susceptibility to gentamicin in rat with obstructive jaundice. Role of lipid peroxidation. Dig Dis Sci 1995; 40: 1060-1064.
131. Abdel-Naim AB, Abdel-Wahab MH, Attia FF. Protective effects of vitamin E and probucol against gentamicin-induced nephrotoxicity in rats. Pharmacol Res 1999; 40: 183-187.
132. Mart?́nez-Salgado C, Eleno N, Tavares P et al., Involvement of reactive oxygen species on gentamicin-induced mesangial cell activation. Kidney Int., 2002 62, 1682-1692.
133. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003; 41: 1447-1452.
134. Koyner JL, Sher Ali R, Murray PT. Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol 2008; 109: e109-e117.
135. Bledsoe G, Crickman S, Mao J et al. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006; 21: 624-633.
136. Kalayarasan S, Prabhu PN, Sriram N et al. Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. Eur J Pharmacol 2009; 606: 162-171.
137. Kourilsky O, Solez K, Morel-Maroger L et al. The pathology of acute renal failure due to interstitial nephritis in man with comments on the role of interstitial inflammation and sex in gentamicin nephrotoxicity. Medicine (Baltimore) 1982; 61: 258-268.
138. Geleilete TJ, Melo GC, Costa RS et al. Role of myofibroblasts, macrophages, transforming growth factor-beta endothelin, angiotensin-II, and fibronectin in the progression of tubulointerstitial nephritis induced by gentamicin. J Nephrol 2002; 15: 633-642.
139. Park JW, Bae EH, Kim IJ et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol 2009; 298: F301-F313.
140. Goto T, Fujigaki Y, Sun DF et al. Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats. Virchows Arch 2004; 444: 362-374.
141. Sue YM, Cheng CF, Chang CC et al. Antioxidation and anti-inflammation by haem oxygenase-1 contribute to protection by tetramethylpyrazine against gentamicin-induced apoptosis in murine renal tubular cells. Nephrol Dial Transplant 2009; 24: 769-777.
142. Cachofeiro V, Goicochea M, de Vinuesa SG et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008: S4-S9.
143. Maldonado PD, Barrera D, Rivero I et al. Antioxidant S-allylcysteine prevents gentamicin-induced oxidative stress and renal damage. Free Radic Biol Med 2003; 35: 317-324. (Pubitemid 37288932)
144. Kadkhodaee M, Khastar H, Faghihi M et al. Effects of co-supplementation of vitamins E and C on gentamicin-induced nephrotoxicity in rat. Exp Physiol 2005; 90: 571-576.
145. Servais H, Ortiz A, Devuyst O et al. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 2008; 13: 11-32.
146. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO J 1991; 10: 2247-2258.
147. 2 and antioxidants have opposite effects on activation of NF-kB and AP-1 in intact cells: AP-1 as secondary antioxidant responsive factor. EMBO J 1993; 12: 2005-2015.
148. Tugcu V, Ozbek E, Tasci AI et al. Selective nuclear factor kappa-B inhibitors, pyrolidium dithiocarbamate and sulfasalazine, prevent the nephrotoxicity induced by gentamicin. BJU Int 2006; 98: 680-686.
149. Markewitz BA, Michael JR, Kohan DE. Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells. J Clin Invest 1993; 91: 2138-2143.
150. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kB/Rel in induction of nitric oxide synthase. J Biol Chem 1994; 269: 4705-4708. (Pubitemid 24239438)
151. Juan SH, Chen CH, Hsu YH et al. Tetramethylpyrazine protects rat renal tubular cell apoptosis induced by gentamicin. Nephrol Dial Transplant 2007; 22: 732-739.
152. Colten HR. Tissue-specific regulation of inflammation. J Appl Physiol 1992; 72: 1-7.
153. Karkar A. Modulation of renal inflammation: therapeutic strategies. Saudi J Kidney Dis Transpl 2008; 19: 1-19.
154. García-Sánchez O, López-Hernández FJ, López-Novoa JM., An integrative view on the role of TGF-b in the progressive tubular deletion associated to chronic kidney disease. Kidney Int., 2010, 77, 950-955.
155. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin 2006; 22: 357-374.
156. Brivet FG, Kleinknecht DJ, Loirat P et al. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24: 192-198.
157. Watanabe A, Nagai J, Adachi Y et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Control Release 2004; 95: 423-433.
158. Fujii K, Nagai J, Sawada T et al. Effect of PEGylation of N-WASP181-200 on the inhibitory potency for renal aminoglycoside accumulation. Bioconjugate Chem 2009; 20: 1553-1558.
159. Antoine DJ, Srivastava A, Pirmohamed M et al. Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells. Biochem Pharmacol 2010; 79: 647-654.
160. Hosaka K, Takeda T, Iino N et al. Megalin and nonmuscle myosin heavy chain IIA interact with the adaptor protein Disabled-2 in proximal tubule cells. Kidney Int 2009; 75: 1308-1315.
161. Gotoh N, Yan Q, Du Z et al. Altered renal proximal tubular endo-cytosis and histology in mice lacking myosin-VI. Cytoskeleton 2010; 67: 178-192.
162. Vlasic-Matas J, Rumboldt Z, Karelovic D. Renoprotective role of nifedipine during gentamicin therapy: randomized controlled trial. Croat Med J 2000; 41: 417-422.
163. Kazierad DJ, Wojcik GJ, Nix DE et al. The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers. J Clin Pharmacol 1995; 35: 196-201.
164. Zhang B, Ramesh G, Uematsu S et al. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 2008; 19: 923-932.
165. Pulskens WP, Teske GJ, Butter LM et al. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS One 2008; 3: e3596.
166. Asehnoune K, Strassheim D, Mitra S et al. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 2004; 172: 2522-2529.
167. Kohanski MA, Dwyer DJ, Wierzbowski J et al. Mistranslation of membrane proteins and two-component system activation trigger aminoglycoside-mediated oxidative stress and cell death. Cell 2008; 135: 679-690.